



1617 \$

RECEIVED  
APR 18 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David J. Grainger et al.  
Title: PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES  
Docket No.: 295.009US3  
Filed: January 4, 2001  
Examiner: T.J. Criares  
Serial No.: 09/754775  
Due Date: February 26, 2003  
Group Art Unit: 1617


Commissioner-for-Patents  
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ An Amendment and Response (12 Pages).
- ☒ Petition for Extension of Time (1 pg.)
- ☒ Authorization to charge to Deposit Account No. 19-0743 in the amount of \$410.00 to cover the Extension of Time Fee.
- ☒ Request to Correct Inventorship Under 37 C.F.R. 1.48(b) (1 pg.).


If not provided for in a separate paper filed herewith, Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By:   
Atty: Janet E. Embretson  
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 10<sup>th</sup> day of April, 2003.

  
Name

  
Signature

**Customer Number 21186**

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

APR 16 2003

PATENT & TRADEMARK OFFICE  
09/754,775

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David J. Grainger et al. Examiner: Theodore Criares  
Serial No.: 09/754,775 Group Art Unit: 1617  
Filed: January 4, 2001 Docket: 295.009US3  
Title: PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH  
TAMOXIFEN ANALOGUES

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.48(b)

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.48(b), please delete the names of Lawrence L. Kunz and Robert W. Schroff as co-inventors of the claims in the above-identified application. This change is necessitated by the cancellation of claims in the Amendment which accompanies this Request. As the invention of Lawrence L. Kunz and Robert W. Schroff is no longer claimed in the present application, correction of inventorship is appropriate and is respectfully requested.

The fee specified in 37 C.F.R. § 1.17(i) is enclosed herewith.

Respectfully submitted,

DAVID J. GRAINGER ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6959

Date April 10, 2003 By Janet E. Embretson  
Janet E. Embretson  
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 10<sup>th</sup> day of April, 2003.

Dawn M. Poole  
Name

Dawn M. Poole  
Signature

RECEIVED  
APR 18 2003  
TECH CENTER 1600/2900